Novel toxicity assay based on human blastocyst-derived stem cells and progenitor cells

Inactive Publication Date: 2008-06-05
CELLARTIS AB (SE)
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]The present invention relates to an in vitro toxicity assay based on human blastocyst-derived stem cells for the detection and/or prediction of toxicity in the human species,

Problems solved by technology

Therefore, in vitro developmental toxicity tests are urgently needed.
However, the EST still aims to predict human toxicity in an animal system.
However, the application of hBS cells in toxicity testing is challenging as these cel

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel toxicity assay based on human blastocyst-derived stem cells and progenitor cells
  • Novel toxicity assay based on human blastocyst-derived stem cells and progenitor cells
  • Novel toxicity assay based on human blastocyst-derived stem cells and progenitor cells

Examples

Experimental program
Comparison scheme
Effect test

Example

Example 1

Culture of hBS Cells, Progenitor Cells and hFF Cells

[0067]The hBS cell lines SA002 and SA002.5 were established and characterised as described previously (Heins et al., 2004, WO03055992), and registered at NIH (http: / / stemcells.nih.gov / research / registry / cellartis.asp) and UK Stem Cell Bank (http: / / www.mrc.ac.uk / Utilities / Documentrecord / index.htm?d=MRC003259). The cell lines were maintained on mitomycin-C inactivated mouse embryonic fibroblasts (mEF) in VitroHES™ medium (Vitrolife, Kungsbacka, Sweden) supplemented with 4 ng / ml human recombinant basic fibroblast growth factor (bFGF) (Invitrogen, Carlsbad, Calif.). Undifferentiated hBS cells were passaged every 4-5 days by mechanical dissociation using the Swemed Stem Cell Tool (Swemed Lab International AB, Billdal, Sweden).

[0068]Fibroblast-like progenitor cells were generated by cutting out pieces of hBS cell colonies in 200×200 μm pieces and placing of the pieces in Petri dishes for aggregation in a medium based of KO-DMEM, ...

Example

Example 2

Proliferation

[0078]In order to determine the optimal cell number to be seeded per well in a 10 day toxicity test a set of proliferation tests was performed. The optimal cell number for seeding has to be in the range where the seeded number of cells is proportional to the signal at the reading day of the test. hFFs, hBS MPs and hBS cells were seeded as triplicates in DMEM supplemented with 10% FBS and 50 U / ml Penicillin / Streptomycin (all Invitrogen) into gelatine (Sigma) coated 96-well plates in a 2-fold dilution series with the highest cell density being 16.000 cells / well for hFF and hBS MPs seeded as single cell suspension and 60.000 cells / well for hBS cells seeded in aggregates of 50 to 100 cells. The plates with hBSC were centrifuged for 5 min at 400 g immediately after cell seeding in order to support the reproducible attachment of the hBS cell aggregates. Culture medium was renewed on day 4 and day 7. On day 10 the intracellular ATP content in the individual wells was ...

Example

Example 3

Cytotoxicity Testing

[0080]hBS cell colonies were dissociated into small aggregates of ca. 50 to 100 cells and seeded into gelatine coated 96-well plates (Nunc, Kamstrupvej, Denmark) in 100 Ml Test medium containing Knock Out DMEM supplemented with 20% FBS, 1% penicillin-streptomycin, 1% Glutamax, 0.5 mmol / l N-mercaptoethanol and 1% non-essential amino acids (all from Invitrogen) at a density of 5000 cells / well. hBS MPs and hFF cells were dissociated into single cells and seeded into gelatine coated 96-well plates (Nunc) in 100 Ml test medium at a density of 500 cells / well. The plates with hBSC were centrifuged directly after seeding for 5 min at 400 g.

[0081]Progenitor cells and hFF cells were dissociated into single cells and seeded into 96-well plates in 100 μl test medium.

[0082]After 24 hours the Cytotoxicity test was started by adding 100 μl toxicity solution to the test wells that had twice the concentration as the required end concentration (day 0). Toxicity medium was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

The invention relates to an in vitro toxicity assay based on human blastocyst-derived stem cells for the detection of toxicity in the human species, which enables novel detection of in vitro human toxicity for a substance and/or more efficiently detects human toxicity compared to non-human assays. The invention can furthermore enable detection of toxicity for substances, which are known to display inter-species differences and the toxic effect was not detectable by toxicological tests in mice.

Description

BACKGROUND OF THE INVENTION[0001]Human blastocyst-derived stem (hBS) cells have the unique ability to differentiate into derivatives of all three germ layers. This characteristic turns them into an exceptional tool in the field of toxicology as they can serve as a “cell factory” for functional cells (Moon S Y, et al, Mol Ther 13(1):5-14, 2006). Moreover, effects of compounds interacting during the process of hBS cell differentiation can be detected which makes them especially valuable in the field of developmental toxicology.[0002]As the new European Chemicals Policy (REACH) will come into effect in 2007, toxicological information is required for more than 30.000 chemicals manufactured or imported in volumes above 1 ton annually (Anon, 2007). Consequently, around 3.9 million additional test animals will potentially be used and the costs to industry are estimated to be around 1.5 Billion Euro, of which 32% are attributed alone to developmental toxicity studies (RPA, 2002). Therefore,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C40B30/06C12Q1/02C12Q1/68
CPCG01N33/5014G01N2500/10G01N33/5073G01N33/5044G01N33/5058G01N33/5061G01N33/5067
Inventor STREHL, RAIMUNDADLER, SARAH
Owner CELLARTIS AB (SE)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap